Glutamate as a therapeutic target in psychiatric disorders.

Program in Cognitive Neuroscience and Schizophrenia, Nathan Kline Institute for Psychiatric Research/New York University School of Medicine, Orangeburg, NY 10962, USA.
Molecular Psychiatry (Impact Factor: 15.15). 12/2004; 9(11):984-97, 979.
Source: PubMed

ABSTRACT Glutamate is the primary excitatory neurotransmitter in the mammalian brain. Glutamatergic neurotransmission may be modulated at multiple levels, only a minority of which are currently being exploited for pharmaceutical development. Ionotropic receptors for glutamate are divided into N-methyl-D-aspartate receptor (NMDAR) and AMPA receptor subtypes. NMDAR have been implicated in the pathophysiology of schizophrenia. The glycine modulatory site of the NMDAR is currently a favored therapeutic target, with several modulatory agents currently undergoing clinical development. Of these, the full agonists glycine and D-serine have both shown to induce significant, large effect size reductions in persistent negative and cognitive symptoms when added to traditional or newer atypical antipsychotics in double-blind, placebo-controlled clinical studies. Glycine (GLYT1) and small neutral amino-acid (SNAT) transporters, which regulate glycine levels, represent additional targets for drug development, and may represent a site of action of clozapine. Brain transporters for D-serine have recently been described. Metabotropic glutamate receptors are positively (Group I) or negatively (Groups II and III) coupled to glutamatergic neurotransmission. Metabotropic modulators are currently under preclinical development for neuropsychiatric conditions, including schizophrenia, depression and anxiety disorders. Other conditions for which glutamate modulators may prove effective include stroke, epilepsy, Alzheimer disease and PTSD.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Nuestro país posee una alta prevalencia e incidencia de casos de tuberculosis (para el año 2012 se registró una morbilidad de 105,2 casos por 100 000 habitantes). En el tratamiento de esta patología pueden desencadenarse numerosas reacciones adversas de índole heterogénea, siendo preponderantes las neuropsiquiátricas, por la polifarmacia antibiótica requerida y otros posibles factores de riesgo del usuario. A partir de un caso de psicosis desencadenada por cicloserina en un paciente con tuberculosis multidrogorresistente, revisamos la literatura pertinente y recomendamos la ponderación individualizada del retiro de la medicación desencadenante del efecto adverso, respecto a la necesidad de mantener la cobertura antibiótica imprescindible y adecuada.
    Revista de neuro-psiquiatría 01/2014; 77(3):179-183.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The World Health Organization estimates that major depression affects about 350 million people all over the world and reports this disorder as the major contributor to the global burden of diseases. Despite the well-defined symptomatology, major depression is a heterogeneous psychiatric disorder whose pathophysiology is not clearly established. Although several treatments are available, most depressed patients do not achieve the complete remission of symptoms. Factors linked to the persistence of the disorder have been investigated, particularly those related to the way of life. Moreover, it has been suggested that nutritional aspects may influence its development. Among them, a diet rich in ω-3 has been associated with a reduced risk of major depression, although its deficiency is associated with depressive disorders.
    Acta Neuropsychiatrica 06/2014; 26(3):178-85. · 0.64 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Ketamine, an N-methyl-D-aspartate receptor (NMDAR) antagonist, has fast-acting antidepressant activities and is used for major depressive disorder (MDD) patients who show treatment resistance towards drugs of the selective serotonin reuptake inhibitor (SSRI) type. In order to better understand Ketamine's mode of action, a prerequisite for improved drug development efforts, a detailed understanding of the molecular events elicited by the drug is mandatory. In the present study we have carried out a time-dependent hippocampal metabolite profiling analysis of mice treated with Ketamine. After a single injection of Ketamine, our metabolomics data indicate time-dependent metabolite level alterations starting already after 2 h reflecting the fast antidepressant effect of the drug. In silico pathway analyses revealed that several hippocampal pathways including glycolysis/gluconeogenesis, pentose phosphate pathway and citrate cycle are affected, apparent by changes not only in metabolite levels but also connected metabolite level ratios. The results show that a single injection of Ketamine has an impact on the major energy metabolism pathways. Furthermore, seven of the identified metabolites qualify as biomarkers for the Ketamine drug response.
    Translational psychiatry. 11/2014; 4:e481.


Available from